Abstract by Jonathan Lynch
Chemistry and Biochemistry
Divalent copper complexes as Influenza A inhibitors
Influenza is a dangerous disease that causes approximately 85,000 deaths annually, and mutations increase its threat with the inevitability of a coming pandemic. As influenza has shown resistance to each drug of the past twenty years, the need is apparent for novel drugs to which influenza is unable to become resistant. Building on the previous drug amantadine, this research proposes to introduce a copper metal center onto an amantadyl scaffold to target the immutable His37 site in the M2A proton channel. By doing so, new drugs can block the M2A channel and prevent viral reproduction. A series of amantadyl carboxolate- or amide-containing ligands were synthesized and complexed with a copper (II) cation. The complexes were then characterized and tested for stability and efficacy. The carboxylate-containing amantadyl copper (II) complexes showed promise as potential anti-influenza drugs, outperforming the amide-containing complexes in every test.